We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

10 hedge funds and large institutions have $80.4K invested in Galmed Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

11% more funds holding

Funds holding: 9 → 10 (+1)

0.09% more ownership

Funds ownership: 0.37% → 0.46% (+0.09%)

44% less capital invested

Capital invested by funds: $143K → $80.4K (-$62.4K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
10
Holders Change
+1
Holders Change %
+11.11%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$27.4K
2
TSS
Two Sigma Securities
New York
+$27.1K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$13.8K
2
Morgan Stanley
Morgan Stanley
New York
-$12.6K
3
SSA
Schonfeld Strategic Advisors
New York
-$511
4
TRCT
Tower Research Capital (TRC)
New York
-$188
5
Wells Fargo
Wells Fargo
California
-$20

GLMD Hedge Fund Activity: Q1 2025 in Review

10 of the 7,469 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2025, worth a combined $80.4K — down 44% from $143K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new GLMD positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 4 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $27.4K. The largest seller was UBS Group, cutting an estimated $13.8K.

  • 10 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2025, up from 9 in Q4 2024.
  • Funds reported $80.4K of Galmed Pharmaceuticals stock for Q1 2025, down 44% quarter-over-quarter.
  • 2 funds opened new Galmed Pharmaceuticals positions in Q1 2025 and 1 closed out, a net change of +1 holder.
  • The largest Galmed Pharmaceuticals buyer in Q1 2025 was Virtu Financial, an estimated $27.4K added.
  • The largest Galmed Pharmaceuticals seller in Q1 2025 was UBS Group, an estimated $13.8K sold.

Based on aggregated 13F filings for Q1 2025.